BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $13.00

by · The Cerbat Gem

BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its target price boosted by JPMorgan Chase & Co. from $12.00 to $13.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Cantor Fitzgerald boosted their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Finally, Wedbush lowered their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Read Our Latest Stock Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $8.17 on Wednesday. The company has a market capitalization of $2.09 billion, a PE ratio of -5.45 and a beta of 0.55. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22. The business’s fifty day moving average is $9.24 and its 200 day moving average is $9.24.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period in the previous year, the business earned $0.15 earnings per share. The firm’s revenue was up 33.6% on a year-over-year basis. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -2.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. BlackRock Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $238,930,000. Jupiter Topco LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $95,268,000. Janus Henderson Group PLC grew its holdings in shares of BioCryst Pharmaceuticals by 20.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock valued at $84,854,000 after purchasing an additional 1,504,120 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares during the last quarter. Finally, Bank of America Corp DE raised its position in BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after purchasing an additional 3,556,208 shares during the period. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.

Further Reading